Research Information System
Inorganic Chemistry Communications, vol.186, 2026 (SCI-Expanded, Scopus)
Quantum dot-based nanozymes (QDNs) represent a cutting-edge convergence of quantum dot technology and enzyme-mimicking nanomaterials, offering outstanding prospects in biomedical fields including bioimaging, biosensing, targeted drug delivery, and photodynamic therapy. Recent advances have leveraged precise surface modification techniques, heteroatom doping, and innovative core–shell architectures to amplify catalytic efficiency, biocompatibility, and specificity, thereby enhancing therapeutic and diagnostic precision. These multifunctional QDNs exhibit superior catalytic performance, stability across physiological conditions, and tunable optical properties, positioning them at the forefront of nanozyme research for combating complex biomedical challenges such as antimicrobial resistance and tumor targeting. Nonetheless, pivotal challenges persist, including inherent toxicity concerns, bioaccumulation, immunogenicity, and gaps in standardization that hinder clinical translation. Addressing these issues involves developing biodegradable and non-toxic quantum dots, optimizing surface passivation, and establishing robust preclinical evaluation protocols. Future directions emphasize integrating multifunctional therapeutic modalities within single QDN platforms, advancing scalable and reproducible manufacturing methodologies, and fostering regulatory frameworks to accelerate clinical adoption. This review underscores both the transformative potential and the critical barriers facing QDNs, guiding their evolution into clinically impactful biomedical tools.